This observation raised the possibility that treatment with anti-PD-1 in combination with IRE could also improve therapeutic outcomes including tumor remission, especially since a subset of mice in our dual therapy regimen failed to clear tumor (see Fig. 4d, e). The gene discussed is PDCD1; the disease is neoplasm.